The Tanner Pharma Group announced on Tuesday that the company would be increasing the European supply of Leukine—a drug used to treat radiation sickness—amid renewed threats of nuclear conflict as a result of Russia’s ongoing war in Ukraine.
In a statement released on March 24, the Tanner Pharma Group said it was expanding the availability of Leukine throughout Europe in collaboration with Partner Therapeutics (which owns the patent for Leukine).
